Work

Drug Development for Alzheimer’s Disease: Microglia Induced Neuroinflammation as a Target?

Year: 2019

Type: review

Abstract: Alzheimer's disease (AD) is one of the most common causes of dementia. Its pathogenesis is characterized by the aggregation of the amyloid-β (Aβ) protein in senile plaques and the hyperphosphorylated tau protein in neurofibrillary tangles in the brain. Current medications for AD can provide temporary help with the memory symptoms and other cognitive changes of patients, however, they are not able to stop or reverse the progression of AD. New medication discovery and the development of a cure for AD is urgently in need. In this review, we summarized drugs for AD treatments and their recent updates, and discussed the potential of microglia induced neuroinflammation as a target for anti-AD drug development.

Source: International Journal of Molecular Sciences

DOI: 10.3390/ijms20030558

Authors: Yuan Dong, Xiaoheng Li, Jinbo Cheng, Lin Hou

Institutions: Qingdao University, Beijing Institute for Brain Disorders, Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,824